{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:39:42Z","timestamp":1793047182726,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary immunodeficiencies are immunological disorders caused by gene mutations involved in immune system development and activation. Recently, activated phosphoinositide 3-kinase delta syndrome (APDS) due to mutations in the phosphoinositide 3-kinase (<jats:italic>PI3K)<\/jats:italic>, <jats:italic>phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit delta gene (PIK3CD<\/jats:italic>), and phosphoinositide 3-kinase regulatory subunit 1 <jats:italic>(PIK3R1<\/jats:italic>) genes have been reported to induce a combined immunodeficiency syndrome leading to senescent T cells, lymphadenopathy, and immunodeficiency. The exact diagnosis of these deficiencies is essential for treatment and prognosis. In recent years, targeted treatment with selective PI3Kd inhibitors has had a significant effect on controlling the symptoms of these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In this case report, we represent a 27-month-old girl with recurrent fever, an increased level of inflammatory markers, and erythema nodosum, who was referred to the rheumatology clinic. In the course of evaluations, because of the lack of clinical improvement with usual treatments, and a history of frequent respiratory infections, combined immunodeficiency was diagnosed in the immunological investigations. Moreover, whole-exome sequencing was performed for her.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The genetic analysis found a novel variant of <jats:italic>PIK3CD<\/jats:italic> (c.1429 G\u2009&gt;\u2009A) in the patient. Following daily antibiotic prophylaxis and monthly IV therapy, the patient\u2019s frequent infections and fevers were controlled.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00859-y","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T07:02:29Z","timestamp":1689836549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunodeficiency due to a novel variant in PIK3CD: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Niloofar","family":"Shashaani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Chavoshzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam Hajiani","family":"Ghotbabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Shiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Sharafian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Shiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"1","key":"859_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","volume":"40","author":"SG Tangye","year":"2020","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24\u201364.","journal-title":"J Clin Immunol"},{"issue":"25","key":"859_CR2","doi-asserted-by":"publisher","first-page":"e3927","DOI":"10.1097\/MD.0000000000003927","volume":"95","author":"CY Chi","year":"2016","unstructured":"Chi CY, Lin CH, Ho MW, Ding JY, Huang WC, Shih HP, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-\u03b3 autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine. 2016;95(25):e3927.","journal-title":"Medicine"},{"issue":"2 Suppl 2","key":"859_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaci.2009.07.053","volume":"125","author":"LD Notarangelo","year":"2010","unstructured":"Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):182\u201394.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"859_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3346\/jkms.2012.27.7.788","volume":"27","author":"JW Rhim","year":"2012","unstructured":"Rhim JW, Kim KH, Kim DS, Kim BS, Kim JS, Kim CH, et al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci. 2012;27(7):788\u201393.","journal-title":"J Korean Med Sci"},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.3389\/fimmu.2019.03148","volume":"10","author":"MC van Zelm","year":"2019","unstructured":"van Zelm MC, Condino-Neto A, Barbouche MR. Editorial: primary Immunodeficiencies Worldwide. Front Immunol. 2019;10:3148.","journal-title":"Front Immunol"},{"issue":"4","key":"859_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ped4.12101","volume":"2","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Ma H, Ma J, Wang D, Zhao Y, Wang T, et al. Clinical and genetic analysis of immunodeficiency-related diseases associated with PIK3CD mutations. Pediatr Invest. 2018;2(4):257\u201362.","journal-title":"Pediatr Invest"},{"issue":"5","key":"859_CR7","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","volume":"136","author":"FA Bonilla","year":"2015","unstructured":"Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186\u2013205. e1-78.","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 1","key":"859_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.tmrv.2009.09.011","volume":"24","author":"N Shehata","year":"2010","unstructured":"Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):28\u201350.","journal-title":"Transfus Med Rev"},{"issue":"Suppl 1","key":"859_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jped.2020.10.004","volume":"97","author":"ES Goudouris","year":"2021","unstructured":"Goudouris ES. Immunodeficiencies: non-infectious manifestations. Jornal de pediatria. 2021;97(Suppl 1):24\u2013s33.","journal-title":"Jornal de pediatria"},{"issue":"2","key":"859_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","volume":"139","author":"TI Coulter","year":"2017","unstructured":"Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597\u2013606e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"6160","key":"859_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage. Sci (New York NY). 2013;342(6160):866\u201371.","journal-title":"Sci (New York NY)"},{"issue":"3","key":"859_CR12","first-page":"8","volume":"3","author":"NZMA Aghamohamadi","year":"2020","unstructured":"Aghamohamadi NZMA. Activated PI3K-Delta syndrome: pathogenesis, clinical manifestations, diagnosis, classification, and management. Immunol Genet J. 2020;3(3):8\u201315.","journal-title":"Immunol Genet J"},{"issue":"5","key":"859_CR13","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","volume":"143","author":"CJ Nunes-Santos","year":"2019","unstructured":"Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation. J Allergy Clin Immunol. 2019;143(5):1676\u201387.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"859_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/jgid.jgid_226_20","volume":"13","author":"I Farouji","year":"2021","unstructured":"Farouji I, Damati A, Chan KH, Ramahi A, Chenitz K, Slim J, et al. Cardiac Tamponade Associated with Human Immunodeficiency Virus-Associated Immune Complex kidney disease. J global Infect Dis. 2021;13(3):151\u20133.","journal-title":"J global Infect Dis"},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"670312","DOI":"10.3389\/fimmu.2021.670312","volume":"12","author":"M Lu","year":"2021","unstructured":"Lu M, Gu W, Sheng Y, Wang J, Xu X. Case Report: activating PIK3CD mutation in patients presenting with granulomatosis with polyangiitis. Front Immunol. 2021;12:670312.","journal-title":"Front Immunol"},{"issue":"2","key":"859_CR16","doi-asserted-by":"publisher","first-page":"AB425","DOI":"10.1016\/j.jaci.2018.12.958","volume":"143","author":"DX Nichols-Vinueza","year":"2019","unstructured":"Nichols-Vinueza DX, Su HC, Rao VK, Bayer DK, Ferguson PJ, Parker R, et al. Granulomatosis with polyangiitis and severe systemic Eosinophilia due to a Novel PIK3CD mutation. J Allergy Clin Immunol. 2019;143(2):AB425.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"859_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","volume":"138","author":"E Elkaim","year":"2016","unstructured":"Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u03b4 syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210\u20138e9.","journal-title":"J Allergy Clin Immunol"},{"key":"859_CR18","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","volume":"9","author":"TI Coulter","year":"2018","unstructured":"Coulter TI, Cant AJ. The treatment of activated PI3K\u03b4 syndrome. Front Immunol. 2018;9:2043.","journal-title":"Front Immunol"},{"issue":"3","key":"859_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","volume":"139","author":"Z Nademi","year":"2017","unstructured":"Nademi Z, Slatter MA, Dvorak CC, Neven B, Fischer A, Suarez F, et al. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. J Allergy Clin Immunol. 2017;139(3):1046\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"859_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaci.2018.08.039","volume":"143","author":"LD Notarangelo","year":"2019","unstructured":"Notarangelo LD. Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase \u03b4 syndrome: who, when, and how? J Allergy Clin Immunol. 2019;143(1):91\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"859_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","volume":"9","author":"ME Maccari","year":"2018","unstructured":"Maccari ME, Abolhassani H, Aghamohammadi A, Aiuti A, Aleinikova O, Bangs C, et al. Disease Evolution and Response to Rapamycin in activated phosphoinositide 3-Kinase \u03b4 syndrome: the european Society for Immunodeficiencies-Activated phosphoinositide 3-Kinase \u03b4 Syndrome Registry. Front Immunol. 2018;9:543.","journal-title":"Front Immunol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00859-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T07:03:37Z","timestamp":1689836617000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00859-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00859-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"5 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}